The organizing focus of the founders and personnel of Orion Therapeutics is that the firm pioneer a new era of RNA therapeutics by delivering breakthrough cures and treatments to previously unmet medical needs. Anchored in work initiated by the firm's principals while grdaute school colleagues at University of Tennessee, the effort has been to develop an innovative siRNA therapy for vascular disease and restenosis. Along the way, it was determined that RNA therapeutic and vaccine developers encountered a common challenge: the critical issue of efficient delivery. This roadblock inspired the team at UTGSM to pioneer a groundbreaking delivery platform—a versatile system that is agnostic to nucleic acid payloads and allows for precise targeting of previously inaccessible areas of the body. With development and utilization of the firm's innovative LNP delivery platform, the effort is to empower researchers and developers in their quest to transform the lives of patients. With a commitment to scientific excellence and patient-centricity, the effort is for a future in which RNA therapies can reach every corner of the body, offering hope, healing, and a better quality of life for all.
